---
title: "UroGen says USPTO allows new patent claims for ZUSDURI, UGN-103 through July 2044"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292763340.md"
description: "UroGen Pharma received a USPTO notice of allowance for a patent application covering mitomycin RTGel-based treatment methods for recurrent LG-IR-NMIBC without TURBT. The patent, expected to expire in July 2044, extends protection for ZUSDURI and the UGN-103 program. Claims are supported by data from the ENVISION and ATLAS clinical trials, strengthening the company’s intellectual property position in non-surgical bladder cancer therapy."
datetime: "2026-07-15T12:02:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292763340.md)
  - [en](https://longbridge.com/en/news/292763340.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292763340.md)
generator: "portal-rs"
---

# UroGen says USPTO allows new patent claims for ZUSDURI, UGN-103 through July 2044

-   UroGen Pharma received a USPTO notice of allowance for a U.S. patent application covering mitomycin RTGel-based treatment methods for recurrent LG-IR-NMIBC without TURBT. \* The patent, once issued, is expected to expire in July 2044, extending protection for ZUSDURI and the UGN-103 program. \* Claims are supported by data from the ENVISION and ATLAS clinical trials, strengthening the company’s IP position in non-surgical bladder cancer therapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [UroGen Pharma to present at Wells Fargo healthcare conference fireside chat](https://longbridge.com/en/news/297781918.md)
- [UroGen grants inducement RSUs to 19 new employees covering up to 117,100 shares](https://longbridge.com/en/news/298034976.md)
- [UroGen Pharma CMO Mark Schoenberg sells 60,677 common shares for $2.86 million](https://longbridge.com/en/news/296828951.md)
- [Alumis (ALMS) After The Lupus Trial Miss, Is A 3.3x P B Premium Too Rich?](https://longbridge.com/en/news/298010346.md)
- [Warner Music Stock And The Copyright Fight Reshaping Music Rights Investing](https://longbridge.com/en/news/297543553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**